Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular IsoformsVACCINESIF3.42023-03-161OAAI
Co-Delivery of the Human NY-ESO-1 Tumor-Associated Antigen and Alpha-GalactosylCeramide by Filamentous Bacteriophages Strongly Enhances the Expansion of Tumor-Specific CD8+T CellsVIRUSES-BASELIF3.52023-03-021OAAI
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19MOLECULAR THERAPYIF122023-03-0111OAAI
DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret ModelDNA疫苗诱导的免疫反应与雪貂模型中较低的病毒SARS-CoV-2滴度相关VACCINESIF3.42022-07-253OAAI
Linear DNA amplicons as a novel cancer vaccine strategyJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHIF12.82022-06-0610OAAI
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal modelsMOLECULAR THERAPYIF122022-01-0145OAAI
Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota compositionONCOIMMUNOLOGYIF6.32021-03-2315OAAI
Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growthJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHIF12.82019-02-1436OAAI